Eli Lilly's quarter wasn't the cleanest but key drug updates speak to its robust pipeline

Eli Lilly's type-2 diabetes drug is off to a fast start, and the FDA agrees to put Lilly's Alzheimer's drug on an accelerated approval pathway.

from US Top News and Analysis https://ift.tt/SNWGoB9
https://ift.tt/YPHV9wg